1 active not recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Inlexisertib: new trials by email Literature Review of Inlexisertib trials Research Report on Inlexisertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies Inlexisertib, Ripretinib - GIST | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 94 | 2023-09-28 | 2026-10-20 |
| Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors Inlexisertib, Trametinib, Binimetinib - Non-Small Cell Lung Cancer, Advanced Solid Tumor | Phase 1 | Terminated | Deciphera Pharmaceuticals, LLC | 91 | 2021-06-15 | 2026-04-08 |
Carcinoma, Non-Small-Cell Lung (1) · Gastrointestinal Stromal Tumors (1) · Neoplasm Metastasis (1)
Deciphera Pharmaceuticals, LLC (2)
United States (2) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Portugal (1) · Spain (1) · Switzerland (1)